Immunogenicity, boostability, and sustainability of the immune response after vaccination against Influenza A virus (H1N1) 2009 in a healthy population
about
Antibody response to influenza A(H1N1)pdm09 among healthcare personnel receiving trivalent inactivated vaccine: effect of prior monovalent inactivated vaccine.Safety and immunogenicity of co-administered MF59-adjuvanted 2009 pandemic and plain 2009-10 seasonal influenza vaccines in rheumatoid arthritis patients on biologicals.Multivariate analysis of factors affecting the immunogenicity of trivalent inactivated influenza vaccine in school-age childrenResponses to A(H1N1)pdm09 influenza vaccines in participants previously vaccinated with seasonal influenza vaccine: a randomized, observer-blind, controlled study.Recombinant influenza H7 hemagglutinins induce lower neutralizing antibody titers in mice than do seasonal hemagglutinins.Seroprotective antibodies to 2011 variant influenza A(H3N2v) and seasonal influenza A(H3N2) among three age groups of US Department of Defense service members.Antibody Persistence in Adults Two Years after Vaccination with an H1N1 2009 Pandemic Influenza Virus-Like Particle Vaccine.Long-Term Persistence of Cell-Mediated and Humoral Responses to A(H1N1)pdm09 Influenza Virus Vaccines and the Role of the AS03 Adjuvant System in Adults during Two Randomized Controlled Trials.Persistence of immunogenicity of a monovalent influenza virus A/H1N1 2009 vaccine in healthy volunteers.Development and evaluation of AS03, an Adjuvant System containing α-tocopherol and squalene in an oil-in-water emulsion.Novel viral vectored vaccines for the prevention of influenza.Profiling of humoral response to influenza A(H1N1)pdm09 infection and vaccination measured by a protein microarray in persons with and without history of seasonal vaccination.Comparing the immunogenicity of AS03-adjuvanted 2009 pandemic H1N1 vaccine with clinical protection in priority risk groups in EnglandSafety and immunogenicity of 2010–2011 A/H1N1pdm09-containing trivalent inactivated influenza vaccine in adults previously given AS03-adjuvanted H1N1 2009 pandemic vaccine: results of a randomized trialInfluenza vaccine effectiveness in the 2011-2012 season: protection against each circulating virus and the effect of prior vaccination on estimates.The effect of age and recent influenza vaccination history on the immunogenicity and efficacy of 2009-10 seasonal trivalent inactivated influenza vaccination in childrenPersistence of Antibodies to Influenza Hemagglutinin and Neuraminidase Following One or Two Years of Influenza Vaccination.Influenza vaccine effectiveness in the community and the householdInfluenza vaccination of pregnant women protects them over two consecutive influenza seasons in a randomized controlled trial.Effects of Repeated Annual Inactivated Influenza Vaccination among Healthcare Personnel on Serum Hemagglutinin Inhibition Antibody Response to A/Perth/16/2009 (H3N2)-like virus during 2010-11.Immunologic correlates of protection and potential role for adjuvants to improve influenza vaccines in older adults.Effects of prior influenza virus vaccination on maternal antibody responses: Implications for achieving protection in the newborns.Repeated Vaccination Does Not Appear to Impact Upon Influenza Vaccine Effectiveness Against Hospitalization With Confirmed Influenza.Seeking help: B cells adapting to flu variability.
P2860
Q30357144-2794C1A0-3491-46F5-86EF-6FAA36BD13E9Q30360610-F554DADE-67D4-410F-BE64-CB2B00C1EFCBQ30362089-A0B41540-5C9C-4BC4-A48C-8EBD911C5DE2Q30362883-26A4B4AF-077A-4CC6-9C42-5FC8743335AFQ30366722-066CDA3B-49FF-4110-ABB7-9C3DFC8A9C1CQ30373137-531301A2-1332-4DCF-9AD4-4BD20391B01EQ30384943-DEE3D800-A2AE-44BF-94B3-08A8880C34A8Q30401398-963F9481-C359-4E31-9D19-E4C395EBBA77Q30411972-BFAC295A-36AD-41DF-9092-41FDB0E49BE8Q30413695-7F68C978-C5E7-4312-B879-3833853C60A0Q30418570-E8959479-58C3-4CA1-B82E-BAF340BD8CBBQ30426571-D76C03D5-EEC6-4307-9C58-40E120D1C2A7Q30427733-8C4C5919-89C5-4CDF-93DC-3D069A04FD4EQ30429170-7EB5243D-C054-49C9-B090-733B0F49DAC3Q33554684-5B4090FC-3703-48EF-AF7F-C97D0A172105Q34648699-AEC9564E-2290-4186-9D30-5BE92878EF93Q36306922-0570EBFA-C6EB-43ED-831F-7988730FA2B6Q36956943-E5DC5AF1-3314-4E70-984D-503D1C11541CQ37107424-799D0C7B-01AC-4A43-B8A3-6CDE50BFC55DQ37568436-A32760AA-4429-4204-9CCB-AF13A1E66A5AQ38124061-D40355CD-0E66-48B9-A5B2-A1DE7FE0DD74Q40094268-09101BEF-34AD-48C2-A7D0-B59E29FF7428Q40280348-E596CFAF-83C7-42D9-A1A1-2B8B5132EE4DQ42201392-30A8B2A1-4D06-4A3D-B885-14F96B1E86F6
P2860
Immunogenicity, boostability, and sustainability of the immune response after vaccination against Influenza A virus (H1N1) 2009 in a healthy population
description
2011 nî lūn-bûn
@nan
2011 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
name
Immunogenicity, boostability, ...... ) 2009 in a healthy population
@ast
Immunogenicity, boostability, ...... ) 2009 in a healthy population
@en
type
label
Immunogenicity, boostability, ...... ) 2009 in a healthy population
@ast
Immunogenicity, boostability, ...... ) 2009 in a healthy population
@en
prefLabel
Immunogenicity, boostability, ...... ) 2009 in a healthy population
@ast
Immunogenicity, boostability, ...... ) 2009 in a healthy population
@en
P2093
P2860
P50
P356
P1476
Immunogenicity, boostability, ...... ) 2009 in a healthy population
@en
P2093
Elisabeth Huijskens
Hennie van Vugt
Johannes Verbakel
Marcel Peeters
Paul Mulder
Ruud van Beek
P2860
P304
P356
10.1128/CVI.05046-11
P577
2011-07-27T00:00:00Z